USPTO serial 87884008
BAUSCH HEALTH
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 7, 2023
- Examiner
- DELGIZZI, RONALD ERNEST
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with BAUSCH HEALTH?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Robert J. Gorman
Robert J. Gorman Bausch + Lomb1400 N. Goodman StreetBausch + LombRochester, NY 14609Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | cardiovascular system; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, hepatologicalrespiratory, neurological, respiratory, neurological, hormonal, psychiatric and immune system related diseases and disorders; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations, namely, immunomodulators; anticholinesterase preparation for the prevention, treatment and alleviation of neurological disorders; Vaginally administered metronidazole gel for use in the treatment of vaginal disorders; intravenous preparations for the treatment of hyperammonemia of all origins; Skin patch for delivering nitroglycerin to a medical patient; anticonvulsants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of stress; pharmaceutical preparations and substances for the prevention, treatment and alleviation of diabetes; pharmaceutical preparations and substances for controlling insulin levels; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension; pharmaceutical preparations and substances for the prevention, treatment and alleviation of angina; pharmaceutical preparations and substances for the cessation of smoking; pharmaceutical preparations and substances for the prevention and treatment of sexually transmitted diseases; pharmaceutical preparations and substances for the prevention and treatment of herpes; pharmaceutical preparations and substances for the prevention, treatment and alleviation of sleep disorders; pharmaceutical preparations and substances for the prevention, treatment and alleviation of acute myocardial infarctions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of symptomatic congestive heart failure; pharmaceutical preparations and substances for the prevention, treatment and alleviation of asymptomatic left ventricular dysfunction; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain and inflammation, namely, anti-inflammatories and pain relief medication; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; Pharmaceutical preparations and substances for the treatment of epilepsy, seizures and neurological and psychological diseases and disorders; Medicines and medicinal preparations for human purposes, namely, to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; sanitary preparations for medical purposes; pharmaceutical preparations to support treatment of hemorrhoids, chronic venous insufficiency and lymphedema; homeopathic pharmaceutics for use in support treatment of hemorrhoids, chronic venous insufficiency and lymphedema and vitamin preparations, all in the form of tablets or powder or soft gelatin capsules or hard gelatin capsules; pharmaceutical preparations and substances for the prevention and treatment of disorders, diseases, conditions and ailments of the cardio-vascular system; pharmaceutical preparations and substances for the prevention and treatment of hypertension; Pharmaceutical preparations for the treatment of nausea, emesis; Acetaminophen sold as an analgesic for the relief of pain; Pharmaceutical products, namely, lipid and triglyceride reducing agents for use in the treatment of cardiovascular and heart disease; Diuretic preparations; pharmaceutical preparations and substances for the prevention, treatment and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the cardiovascular system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Parkinson's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Huntington's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of amyotrophic lateral sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Alzheimer's disease; pharmaceutical preparations and substances for the prevention, treatment and alleviation of Tourette Syndrome; pharmaceutical preparations and substances for the prevention, treatment and alleviation of epilepsy; pharmaceutical preparations and substances for the prevention, treatment and alleviation of multiple sclerosis; pharmaceutical preparations and substances for the prevention, treatment and alleviation of cardio-pulmonary disorders, diseases, conditions, and ailments; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions, and ailments of the circulatory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of hypertension, high blood pressure, heart failure and ventricular dysfunction; pharmaceutical preparations and substances for the prevention, treatment and alleviation of viral and infectious diseases; pharmaceutical preparations and substances for the prevention, treatment and alleviation of central nervous system disorders, diseases, conditions and ailments, namely, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, encephalitis, cerebral palsy, insomnia, mood disorders, bipolar disorder, seizure disorders; pharmaceutical preparations and substances, namely, fibrinolytic or thrombolytic agents; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the respiratory system; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the endocrine system; pharmaceutical preparations for the treatment of immunologic diseases, namely, auto immune motility diseases, immunologic deficiency syndromes, auto immune diseases, Acquired Immune Deficiency Syndrome (AIDS), hypersensitivity, allergies, tumors of the immunological organs; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments of the musculoskeletal system, namely, bone diseases and bone degenerative conditions; pharmaceutical preparations and substances for the prevention, treatment and alleviation of migraines; pharmaceutical preparations and substances for use in oncology; pharmaceutical preparations and substances for the treatment of polycystic ovary syndrome; pharmaceutical preparations and substances for the treatment of infertility; pharmaceutical preparations and substances for the treatment of diabetes; pharmaceutical preparations and substances for the treatment of heart disease; pharmaceutical preparations and substances for the treatment of pain; pharmaceutical preparations and substances for the treatment of cardiovascular disease; pharmaceutical preparations and substances for the treatment of depression and social anxiety; pharmaceutical preparations and substances for the treatment of insomnia; pharmaceutical preparations and substances for the treatment of sleep disorders; pharmaceutical preparations and substances for the treatment of migraine and neurological disorders; Pharmaceutical preparations for the treatment of cancer, neurological and dermatological disorders; pharmaceutical preparations for the treatment of myasthenia gravis, depression, mood/anxiety conditions, solar keratoses and cancer; antidepressants; tranquilizers; nasal spray preparations; Pharmaceutical preparations for the treatment of neuromuscular conditions; Pharmaceutical preparations, namely, retinoids, for the treatment of skin related diseases, cancer and precancerous conditions, and disorders related to the modulation of apoptosis; vitamin supplement distributed by prescription only; pharmaceutical preparations, namely, an oral glucose gel for the treatment of low blood sugar; pharmaceutical preparation for the treatment of headaches; pharmaceutical preparations;, namely, diazepam rectal gel; Methyltestosterone for use in the treatment of hormone deficiencies; medicated skin lotion for the relief of itch caused by insect bites, eczema, sunburn and poison ivy; Preparations and substances for the relief of anorectal discomfort, inflammation, and irritation; hemorrhoidal suppositories; Pharmaceutical preparations for the treatment of irritable bowel syndrome; Drugs to treat opioid-induced constipation; Psychotropic preparations; Cough medicine in the nature of saline solution, namely, a spray for nasal dryness due to allergies, cold and flu; Dermotherapeutic preparation for use in the treatment of obesity; pharmaceutical preparations for the treatment of neurological disorders and movement disorders; antiobesity agent in the nature of a pharmaceutical preparation; and alleviation of pain; anti-depressants; pharmaceutical preparations and substances for the prevention, treatment and alleviation of anxiety, depression, depressive disorders and mental illness; tranquilizers and sedatives; pharmaceutical preparations and substances for the prevention, treatment and alleviation of disorders, diseases, conditions and ailments | ACTIVE | Mar 12, 2014 |
| 041 | Providing on-line publications in the nature of newsletters, pamphlets and bulletins in the field of health issues; newsletters, articles, informational brochures and web-based tools | ACTIVE | Mar 12, 2014 |
| 044 | Providing a website featuring information and advice in the field of health issues | ACTIVE | Mar 12, 2014 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Bausch & Lomb Incorporated
- Other trademarks owned by Bausch & Lomb Incorporated
- Other trademarks owned by Bausch & Lomb Incorporated
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 044
- Similar marks named BAUSCH HEALTH
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 14, 2026 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 14, 2026 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 14, 2026 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Sep 10, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Jul 25, 2025 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 6, 2023 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Feb 7, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 7, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 6, 2023 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jan 5, 2023 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jan 3, 2023 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jan 1, 2023 | IUAF | USE AMENDMENT FILED | — |
| Jan 1, 2023 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Dec 28, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 21, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Dec 14, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Oct 10, 2022 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 10, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 10, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 10, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 10, 2022 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jul 12, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 11, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Jul 11, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Jun 28, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Jun 28, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 23, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Mar 9, 2022 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| Nov 9, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Nov 7, 2021 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Nov 7, 2021 | EXT4 | SOU EXTENSION 4 FILED | — |
| Nov 7, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 16, 2021 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 16, 2021 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 16, 2021 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jun 1, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 30, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| May 30, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| May 30, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Dec 3, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Dec 1, 2020 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Dec 1, 2020 | EXT2 | SOU EXTENSION 2 FILED | — |
| Dec 1, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Nov 25, 2020 | ASCK | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | — |
| May 19, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| May 15, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| May 15, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| May 15, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 11, 2020 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 11, 2020 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 11, 2020 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 11, 2020 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 11, 2020 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Dec 31, 2019 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Nov 5, 2019 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 5, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 16, 2019 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 28, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 28, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 28, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 28, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 28, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 7, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 6, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 6, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 8, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 8, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 8, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 15, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 14, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 14, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2019 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 14, 2019 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Aug 15, 2018 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2018 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 15, 2018 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 9, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 13, 2018 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 13, 2018 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 27, 2018 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 23, 2018 | NWAP | NEW APPLICATION ENTERED | — |